[go: up one dir, main page]

SG162811A1 - Nanoparticulate and controlled release compositions comprising aryl- heterocyclic compounds - Google Patents

Nanoparticulate and controlled release compositions comprising aryl- heterocyclic compounds

Info

Publication number
SG162811A1
SG162811A1 SG201004372-7A SG2010043727A SG162811A1 SG 162811 A1 SG162811 A1 SG 162811A1 SG 2010043727 A SG2010043727 A SG 2010043727A SG 162811 A1 SG162811 A1 SG 162811A1
Authority
SG
Singapore
Prior art keywords
nanoparticulate
ziprasidone
aryl
controlled release
heterocyclic compounds
Prior art date
Application number
SG201004372-7A
Inventor
John Devane
Paul Stark
Niall Fanning
Gurvinder Rekhi
Scott Jenkins
Gary Liversidge
Original Assignee
Elan Pharma Int Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/372,857 external-priority patent/US20060240105A1/en
Application filed by Elan Pharma Int Ltd filed Critical Elan Pharma Int Ltd
Publication of SG162811A1 publication Critical patent/SG162811A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention provides a composition comprising ziprasidone useful in the treatment and prevention of schizophrenia and similar psychiatric disorders. In one embodiment, the composition comprises nanoparticulate particles comprising ziprasidone and at least one surface stabilizer. The nanoparticulate particles have an effective average particle size of less than about 2000 nm. In another embodiment, the composition comprises a modified release composition that, upon administration to a patient, delivers ziprasidone in a bimodal, multimodal or continuous manner. The invention also relates to dosage forms containing such compositions, and to methods for the treatment and prevention of schizophrenia and similar psychiatric disorders. (No Suitable Figure)
SG201004372-7A 2005-06-20 2006-06-19 Nanoparticulate and controlled release compositions comprising aryl- heterocyclic compounds SG162811A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69209605P 2005-06-20 2005-06-20
US11/372,857 US20060240105A1 (en) 1998-11-02 2006-03-10 Multiparticulate modified release composition

Publications (1)

Publication Number Publication Date
SG162811A1 true SG162811A1 (en) 2010-07-29

Family

ID=37809174

Family Applications (1)

Application Number Title Priority Date Filing Date
SG201004372-7A SG162811A1 (en) 2005-06-20 2006-06-19 Nanoparticulate and controlled release compositions comprising aryl- heterocyclic compounds

Country Status (12)

Country Link
EP (1) EP1901722A4 (en)
KR (1) KR20080024206A (en)
CN (1) CN101879140A (en)
AU (1) AU2006285349A1 (en)
BR (1) BRPI0612297A2 (en)
CA (1) CA2613474A1 (en)
EA (1) EA200800092A1 (en)
HK (1) HK1117060A1 (en)
IL (1) IL188093A0 (en)
NO (1) NO20076628L (en)
SG (1) SG162811A1 (en)
WO (1) WO2007027273A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20100131477A (en) * 2008-03-07 2010-12-15 화이자 인코포레이티드 Methods, dosage forms, and kits for administering ziprasidone without food
DE102008045854A1 (en) 2008-09-05 2010-03-11 Tiefenbacher Pharmachemikalien Alfred E. Tiefenbacher Gmbh & Co. Kg Particles of ziprasidone and a disintegrant containing pharmaceutical composition
WO2010082855A1 (en) * 2009-01-15 2010-07-22 Zaklady Farmaceutyczne Polpharma Sa Pharmaceutical compositions comprising ziprasidone free base or ziprasidone hydrochloride and the method for their preparation
WO2011148253A2 (en) 2010-05-25 2011-12-01 Aurobindo Pharma Limited Solid dosage forms of antipsychotics
WO2015095230A1 (en) 2013-12-16 2015-06-25 Massachusetts Institute Of Technology Micromolded or 3-d printed pulsatile release vaccine formulations
CN106061292B (en) 2013-12-16 2020-01-21 麻省理工学院 Fortified micronutrient salt formulations
MA41611A (en) * 2015-02-23 2018-01-02 Omthera Pharmaceuticals Inc MILLI-CAPSULE PREPARATIONS CONTAINING FREE POLYINSATURATED FATTY ACIDS

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
AU660852B2 (en) * 1992-11-25 1995-07-06 Elan Pharma International Limited Method of grinding pharmaceutical substances
US6150366A (en) * 1998-06-15 2000-11-21 Pfizer Inc. Ziprasidone formulations
US8293277B2 (en) * 1998-10-01 2012-10-23 Alkermes Pharma Ireland Limited Controlled-release nanoparticulate compositions
NZ511442A (en) * 1998-11-02 2003-02-28 Elan Corp Plc Multiparticulate modified release composition for multiple dosing of ADD patients with methylphenidate HCl
GEP20033113B (en) * 1999-05-27 2003-11-25 Pfizer Products Inc Us Ziprasidone Suspension
KR20050055781A (en) * 2002-10-25 2005-06-13 화이자 프로덕츠 인크. Novel injectable depot formulations
AR046811A1 (en) * 2003-09-02 2005-12-28 Imran Ahmed ORAL DOSAGE FORMS OF ZIPRASIDONE OF SUSTAINED LIBERATION
CN101166514A (en) * 2005-04-13 2008-04-23 辉瑞产品公司 Injectable depot formulations and methods for providing sustained release of nanoparticle compositions

Also Published As

Publication number Publication date
CN101879140A (en) 2010-11-10
NO20076628L (en) 2008-03-12
IL188093A0 (en) 2008-03-20
WO2007027273A1 (en) 2007-03-08
EA200800092A1 (en) 2008-06-30
HK1117060A1 (en) 2009-01-09
CA2613474A1 (en) 2007-03-08
BRPI0612297A2 (en) 2010-11-03
KR20080024206A (en) 2008-03-17
AU2006285349A1 (en) 2007-03-08
EP1901722A4 (en) 2011-06-15
EP1901722A1 (en) 2008-03-26

Similar Documents

Publication Publication Date Title
NZ573555A (en) Nanoparticulate posaconazole formulations
SG161203A1 (en) Nanoparticulate tacrolimus formulations
HUE040393T2 (en) Formulations comprising nanoparticulate meloxicam
SG162811A1 (en) Nanoparticulate and controlled release compositions comprising aryl- heterocyclic compounds
EA200701195A1 (en) CONTAINING CEFALOSPORIN COMPOSITIONS WITH NANOPARTICLES AND WITH CONTROLLED DELIVERY
WO2007053197A3 (en) Nanoparticulate acetaminophen formulations
ATE457718T1 (en) STERILE FILTERED NANOPARTICLE FORMULATIONS OF BUDESONIDE WITH TYLOXAPOL AS SURFACE STABILIZER
EA200701997A1 (en) COMPOSITION OF BISPHOSPHONATE NANOPARTICLES
ATE419835T1 (en) NYSTATIN NANOPARTICLE COMPOSITIONS
EP1895984B8 (en) Nanoparticulate imatinib mesylate formulations
EP2481402A3 (en) Nanoparticle comprising rapamycin and albumin as anticancer agent
WO2007035348A3 (en) Nanoparticulate aripiprazole formulations
WO2006110809A3 (en) Nanoparticulate lipase inhibitor formulations
CY1107810T1 (en) COMPOSITIONS WHICH HAVE A COMBINATION OF IMMEDIATE LIBERATION AND CONTROLLED LIBERTY CHARACTERISTICS
WO2007033239A3 (en) Nanoparticulate tadalafil formulations
EA200702444A1 (en) COMPOSITIONS WITH FLOATED HEATING NANOPARTICLES
HK1079783A1 (en) 3,6-disubstituted azabicyclo 3.1.0 hexane derivatives useful as muscarinic receptor antagonists
WO2008030209A3 (en) Nanoparticulate and controlled release compositions comprising a platelet aggregation inhibitor
WO2006135689A3 (en) Nanoparticulate ebastine formulations
WO2006138421A3 (en) Nanoparticulate azelnidipine formulations
BRPI0614080A2 (en) COMPOSITION AND METHOD FOR THE PREPARATION OF A NANOPARTICULATE cephalosporin, FOR THE TREATMENT OF BACTERIAL DISEASE AND FOR THE PREVENTION AND/OR TREATMENT OF OSTEOPOROSIS
UA95088C2 (en) Composition comprising at least one anticancer drug and at least one polymer and reducing chemotherapy-induced alopecia, process for the preparation thereof
WO2007146943A3 (en) Nanoparticulate kinase inhibitor formulations
GB2442366A (en) Nanoparticulate and controlled release compositions comprising prostaglandin derivatives
WO2007106111A3 (en) Nanoparticulate and controlled release compositions comprising nilvadipine